HAVCR2 and cancer: Additionally, Treg downregulates the level of IL-2 and upregulates the level of programmed death-1 (PD-L1), T-cell immunoglobulin mucin-3 (TIM-3), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) etc. and stimulates cancer immune escape [122].